.terms_of_service_block{display:block;}.terms_of_service_block.terms_btn_toggle{display:none;}

Merck & Company Inc. Common Stock (new) (NYSE:MRK)

Real-time price:$78.97

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 31 May 2025

Charlene Vos

2025-05-21 03:39:45

Bullish

Quantitative fundamental analysis

Our new podcast deep-dives into how generative AI tools, robots, avatars, and large language models (LLM) help substantially enhance human productivity. Today, the mainstream LLMs include OpenAI ChatGPT, Google Gemini and NotebookLM, Microsoft Copilot, Anthropic Claude, Alibaba Qwen, DeepSeek, Meta Llama, Amazon Alexa and Nova, Twitter xAI Grok, and Perplexity.

$META $MSFT $GOOG $GOOGL $AAPL $AMZN $BABA $BIDU $TME $KKR $IQ $BILI $JD $PDD $IONQ 

$NVDA $AMD $INTC $ARM $CSCO $ORCL $T $TMUS $VZ $TSLA $NIO $RIVN $NET $CRWD $IBM $TSM 

$SNPS $RACE $ZIM $MRK $AMGN $JNJ $BMY $LLY $NVO $GSK $COST $HPE $HD $PG $WMT $TGT 




This fun podcast is about 10 minutes long (with smart AI podcast generation from Google NotebookLM). https://bit.ly/4elAFKv

The top generative artificial intelligence (Gen AI) tools include OpenAI ChatGPT, Google Gemini and NotebookLM, Microsoft Copilot, Meta Llama, Amazon Alexa and Nova, Anthropic Claude, Twitter xAI Grok, Perplexity, Alababa Qwen, DeepSeek, Mistral, Midjourney, Synthesia, Jasper, and so forth. These Gen AI search engines apply large language models (LLM) and content generation tools to help enhance human lives with significantly greater productivity. Productivity gains often manifest in the common forms of AI-driven scripts, articles, images, podcasts, films, movies, and many other online contents. Gen AI avatars help translate text, imagery, and sound recognition into interpretable contents within only seconds. This recent Gen AI hype transforms and even revolutionizes the current high-tech stock market rally. Since the successful launch of OpenAI’s ChatGPT back in November 2022, these Gen AI virtual assistants have grown significantly to leverage the high performance of AI semiconductor microchips from Nvidia, AMD, Micron, TSMC, Pegatron, and many of their trade partners. In recent quarters, stock market investors revive their current interest in this modern Gen AI technology worldwide.

Foundational LLMs and Gen AI virtual tools, assistants, and avatars substantially enhance the high-skill process of online content generation. As a result, the stocks of Gen AI companies have had more than double-digit improvements in their stock market valuation, top-line sales revenue growth, and bottom-line profitability. Gen AI technology can help create new content generation in the form of text, imagery, video, audio, and code through natural language communication, rather than code snippets and arcane programming languages. These key transformative features distinguish the current Gen AI technology from the vast majority of its predecessors. We can view this Gen AI technology as the third generation of AI software research. Earlier iterations of AI technology either required computer scientists and software engineers to write deterministic code programs to perform specific tasks (Software 1.0), or required these specialists to statistically train complex neural networks on big data for specific tasks and predictions (Software 2.0). With Software 3.0 today, the foundational models leverage out-of-the-box capabilities to enhance their niche businesses with natural language reasons, explanations, and knowledge spillovers worldwide. These Gen AI base models help substantially transform both the logical and reasonable content generation through open-source application programming interfaces (API) without any laborious collection of big data.

This Gen AI transformation has begun to translate into a new economic reality. In some cases, developer productivity gains amount to double-digit percentages (at least 15% to 20% per annum) via Gen AI technology. This Gen AI technology can further enhance human-robot interactions and several other adjacent applications, especially in traditional service markets such as law, finance, medicine, illustration, as well as audio, voice, and video generation with smart data analytics. Many stock market investors regard this Gen AI technology as a major platform shift across all aspects of both the consumer and enterprise experiences.

This Gen AI transformation can cause new profound ripple effects, macroeconomic consequences, and policy implications. Recent empirical studies show that Gen AI usage can help boost U.S. annual labor productivity growth by 1.5-2.5 percentage points over the current decade. In the U.S. and many other rich economies, AI can eventually help raise annual global GDP by 7% to 15%. This global productivity lift can turn a relatively narrow AI-led U.S. stock market rally into a much broader one over the longer run. Specifically, S&P 500 stocks have already experienced 9% to 25% increases in fair asset market valuation in recent years, especially in the post-pandemic period. This Gen AI stock market trend turns out to be the new friend for many institutional investors worldwide.

However, the neural networks of these Gen AI tools differ from the neural networks of human brains. Gen AI machines can indeed perform reflexive statistical analysis, but these machines have virtually little capacity for human-like logical deliberations and reasons. Although these Gen AI machines learn and recognize patterns in text, imagery, audio, and video etc, the vast majority of machine-learning algorithms still revolve around the deep statistics of both words and proper responses to prompts. Specifically, these machine-learning algorithms cannot function like human brains to completely understand abstract concepts, such as the broad business judgment rule in law, dynamic equilibrium fair market valuation in finance, and the dopamine hypothesis in medicine. As a result, there is no internal model for these AI machine-learning algorithms to understand the world around them. One day the human race may achieve artificial general intelligence (AGI), but we are still far from AGI today. No finite dollar amount of stock market investment can change this current reality. When push comes to shove, stock market investors would need to make prudent investment decisions in support of better stock portfolio profitability, resilience, and diversification.

In terms of stock market valuation, the current AI stock market rally is pretty much like the past innovation booms. During the past innovation-led productivity booms, such as the widespread adoption of electricity from 1919 to 1929 and PCs and the Internet from 1996 to 2005, sharp and steady increases in stock market prices and returns turn into asset bubbles over the medium. These asset bubbles eventually burst in due course. In response to the widespread adoption of electricity, the Great Depression ensued in the 1930s. In response to the dotcom bubble, the subprime mortgage crisis and Global Financial Crisis arose in 2008-2009. Although the rising tide seems to lift all boats in the AI-led high-tech sector, the current AI stock market rally would eventually experience a more reasonable correction in due course.

In the meantime, the vast majority of Gen AI stocks continue to trade at reasonably attractive P/E and P/B multiples. It can be quite reasonable for many tech titans to drive the current powerful AI stock market rally. In light of this positive platform shift, the current AI stock market rally may or may not be a fundamentally shallow hype cycle. To the extent that many tech titans continue to apply AI foundational models for business purposes, the picks-and-shovels businesses are likely to benefit from this continuation. For AI, these fundamental picks-and-shovels businesses include semiconductor microchip manufacturers (Nvidia, AMD, TSMC, Micron, Intel, and so on), cloud computing hyperscalers (Amazon, Google, Microsoft, IonQ, Alibaba, and Tencent), and online infrastructure companies (Cisco, Oracle, AT&T, T-Mobile, and Verizon).

Below we provide hyperlinks to many other recent podcasts, surveys, research articles, and blog posts on global macro-finance, asset return prediction, trade, technology, fiscal-monetary policy coordination, and fundamental industry analysis for stock market investors worldwide. Key technological advancements include generative artificial intelligence (Gen AI) large language models (LLM), electric vehicles (EV), autonomous robotaxis (AR), virtual reality (VR) headsets, semiconductor microchips, high-speed broadband networks, telecoms, cloud services, social media platforms, quantum computers, and pharmaceutical treatments, medications, and therapies.

American exceptionalism often turns out to be the heuristic rule of thumb for better economic growth, low and stable inflation, full employment, and macro-financial stability.

In the broader modern monetary policy context, central banks learn to weigh the trade-offs between output and inflation expectations and macro-financial stress conditions.

Today, tech titans, billionaires, serial entrepreneurs, and venture capitalists continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

Artificial intelligence continues to reshape the current global market for better biotech advances, medical innovations, and healthcare services.

The global market for GLP-1 anti-obesity weight-loss treatments now grows substantially to benefit more than 1 billion people worldwide by 2030.

Is higher stock market concentration good or bad for Corporate America?

Geopolitical alignment often reshapes and reinforces asset market fragmentation in the broader context of financial deglobalization.

The global cloud infrastructure helps accelerate the next high-tech revolutions in electric vehicles (EV), virtual reality (VR) headsets, artificial intelligence (AI) online services, and the metaverse.

The new homeland industrial policy stance tilts toward greater global resilience across the major high-tech supply chains worldwide.

China poses new threats to the U.S. and its western allies.

How can generative AI tools and LLMs help enhance human productivity?

What are the macrofinancial ripple effects of central bank digital currency (CBDC) design, issuance, and broad user adoption?

Both BYD and Tesla have become serious global manufacturers of electric vehicles (EV) worldwide.

With U.S. fintech patent approval, accreditation, and protection for 20 years, our AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors worldwide.

We build, design, and delve into our new and non-obvious proprietary algorithmic system for smart asset return prediction and fintech network platform automation. Unlike our fintech rivals and competitors who chose to keep their proprietary algorithms in a black box, we open the black box by providing the free and complete disclosure of our U.S. fintech patent publication. In this rare unique fashion, we help stock market investors ferret out informative alpha stock signals in order to enrich their own stock market investment portfolios. With no need to crunch data over an extensive period of time, our freemium members pick and choose their own alpha stock signals for profitable investment opportunities in the U.S. stock market.

Smart investors can consult our proprietary alpha stock signals to ferret out rare opportunities for transient stock market undervaluation. Our analytic reports help many stock market investors better understand global macro trends in trade, finance, technology, and so forth. Most investors can combine our proprietary alpha stock signals with broader and deeper macrofinancial knowledge to win in the stock market.

Through our proprietary alpha stock signals and personal finance tools, we can help stock market investors achieve their near-term and longer-term financial goals. High-quality stock market investment decisions can help investors attain the near-term goals of buying a smartphone, a car, a house, good health care, and many more. Also, these high-quality stock market investment decisions can further help investors attain the longer-term goals of saving for travel, passive income, retirement, self-employment, and college education for children. Our AYA fintech network platform empowers stock market investors through better social integration, education, and technology.

Generative artificial intelligence (Gen AI) uses large language models (LLM) to create online contents with better human productivity. - Blog - AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors.

We explain technological advances in Generative Artificial Intelligence (Gen AI).

https://ayafintech.network/blog/generative-artificial-intelligence-uses-large-language-models-and-content-generation-tools-to-enhance-human-productivity/

Olivia London

2025-05-17 02:50:53

Bullish

Quantitative fundamental analysis

Our new podcast deep-dives into how the global market for GLP-1 anti-obesity weight-loss treatments now grows substantially to benefit more than 1 billion people worldwide by 2030.

$MRK $BMY $LLY $NVO $JNJ $AMGN $BNT $MRNA $PFE $AZN $GSK $C $BAC $JPM $WFC $GS $MS 

$PNC $COST $WMT $TGT $HD $PG $CVX $AMZN $META $MSFT $AAPL $GOOG $GOOGL $BRK.B $T 

$BRK.A $TMUS $VZ $DIS $NFLX $WRB $BABA $TME $BIDU $BILI $JD $PDD $KKR $IQ $IONQ $ZIM 




This fun podcast is about 10 minutes long (with smart AI podcast generation from Google NotebookLM). https://bit.ly/4bz6vmI

The new third-generation GLP-1 medications for obesity treatment and weight loss treatment, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, now begin to become more prevalent and more pervasive worldwide. These medications show far higher weight loss efficacy than prior first-generation and second-generation medications. The latest GLP-1 medications further show long prevalent safety track records for the treatments of diabetes, heart diseases, and several kinds of cancers. However, the current U.S. prices for these new GLP-1 medications are extremely high (about $15,000 per patient per year). In the meantime, not all people with obesity can take these new GLP-1 medications because they are now prohibitively costly and U.S. insurance coverage remains partial and incomplete. Despite these current hurdles, obstacles, and impediments for broader GLP-1 drug adoption, we now expect the global market for GLP-1 obesity and weight loss medications to grow substantially to benefit more than 1 billion people with obesity worldwide by 2030.

GLP-1 medications are the first in a long history of weight loss medications to target the critical brain pathways that regulate both food intake and energy storage. As a result, GLP-1 patients feel less hungry and so crave food much less. As the third-generation medications for obesity treatment, these new GLP-1 medications often lead to 23%-25% average weight losses among GLP-1 patients (versus the single-digit average weight losses of prior medications).

While GLP-1 medications show tremendous promise in weight loss treatment, the global market for these new medications remains only a fraction of all of the people with obesity worldwide. Some patients are not medically able to take these GLP-1 medications, especially since each of these medications requires an injection by a needle. Also, these latest GLP-1 medications are shown to be effective only when patients continue to take these medications almost on a daily basis. A current lack of comprehensive insurance coverage by Medicare, Medicaid, and private insurers remains a major obstacle to wider GLP-1 drug adoption and usage in America and other countries. The current healthcare insurance programs only cover GLP-1s for the wider treatments of obesity-driven diseases such as diabetes, heart diseases, and some types of cancers, but there is now no insurance coverage solely for the treatment of obesity alone.

In addition to supply chain shortages and bottlenecks for GLP-1 mass production, the current hurdles, obstacles, and impediments impose hard high-cost limits and constraints on the size of the global market for GLP-1 medications in the near-to-medium term. Some recent estimates show that the U.S. GLP-1 patient population is likely to grow substantially from 2 million people with obesity today to at least 15 million people with obesity in 2030 (about 15% of the U.S. adults with obesity). On the basis of these recent estimates, we can now expect the global market for GLP-1 medications to increase substantially from $10 billion today to almost $100 billion by 2030.

Over the next few years, we expect U.S. employer insurance coverage for GLP-1 medications to increase substantially from approximately 50% of U.S. employers today due to greater U.S. employee healthcare needs and the significantly positive health benefits of GLP-1 medications. As several pharmaceutical titans direct their R&D efforts into some further developments of GLP-1 medications, it is reasonable for investors to expect more intense competition to result in lower prices for GLP-1 medications. Further, the new GLP-1 treatments of other obesity-driven diseases, specifically heart diseases, diabetes, and some types of cancers etc, can go a long way in empowering Medicare, Medicaid, and numerous private insurers to broaden their health insurance coverage of GLP-1 medications. In the meantime, however, U.S. Congress prohibits Medicare and Medicaid from covering GLP-1 medications today because of their budget-busting sky-high prices.

We can expect U.S. health insurance coverage to broaden substantially if the new GLP-1 medications show promise in treating serious health conditions well beyond obesity. Additional health conditions can include heart diseases, diabetes, as well as some kinds of cancers. The FDA’s recent approval of Novo Nordisk’s Wegovy, semaglutide, for the treatment of heart diseases has led to Medicare coverage of Wegovy for this new indication. Current studies for the treatments of sleep apnea, liver impairment, and other diseases can result in similarly favorable outcomes of broader Medicare coverage of GLP-1 medications. Some recent positive estimates show that the wider GLP-1 treatments of diseases can probably benefit 70 million obese U.S. patients by 2030. These positive ripple effects and chain reactions can cause greater economic benefits beyond the biotech and pharmaceutical sectors. As a result of GLP-1 medications with higher weight-loss efficacy, U.S. adults with prior obesity would have substantially greater and broader needs and demands for day-to-day food items, beverages, many other consumer staples, beauty products, and even air travel round-trips.

With the concomitant positive health improvements, the next widespread adoption of GLP-1 medications can cause better economic growth, employment, and labor productivity in America. U.S. GDP can probably rise by 0.5 to 2 percentage points in the long run if at least 30 million U.S. adults with obesity take these medications. Specifically, U.S. GDP can increase more substantially by 1.35 to 2.55 percentage points if all 70 million U.S. adults with obesity take such medications. However, the American government would face fiscal strain if both Medicare and Medicaid start to provide complete health insurance coverage to 40% of U.S. adults with obesity. This fiscal strain would likely amount to $1 trillion per year if all 40% of U.S. adults with obesity take GLP-1 medications at the current high prices ($15,000 per patient per year). This dollar amount is about the current size of Medicare and about 20% of how much Americans spend on healthcare each year. Although there are clear health benefits for U.S. adults with obesity to take GLP-1 medications, broad health insurance coverage would be enormously expensive for the U.S. government. We believe the next wave of GLP-1 technological advancements can help alleviate this fiscal concern for smarter and better healthcare solutions to weight loss treatments in due course.

Below we provide hyperlinks to many other recent podcasts and articles on global macro-finance, asset return prediction, and fundamental industry analysis for stock market investors.

American exceptionalism often turns out to be the heuristic rule of thumb for better economic growth, low and stable inflation, full employment, and macro-financial stability.

In the broader modern monetary policy context, central banks learn to weigh the trade-offs between output and inflation expectations and macro-financial stress conditions.

Today, tech titans, billionaires, serial entrepreneurs, and venture capitalists continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

Artificial intelligence continues to reshape the current global market for better biotech advances, medical innovations, and healthcare services.

The global market for GLP-1 anti-obesity weight-loss treatments now grows substantially to benefit more than 1 billion people worldwide by 2030.

Is higher stock market concentration good or bad for Corporate America?

Geopolitical alignment often reshapes and reinforces asset market fragmentation in the broader context of financial deglobalization.

The global cloud infrastructure helps accelerate the next high-tech revolutions in electric vehicles (EV), virtual reality (VR) headsets, artificial intelligence (AI) online services, and the metaverse.

The new homeland industrial policy stance tilts toward greater global resilience across the major high-tech supply chains worldwide.

China poses new threats to the U.S. and its western allies.

How can generative AI tools and LLMs help enhance human productivity?

What are the macrofinancial ripple effects of central bank digital currency (CBDC) design, issuance, and broad user adoption?

Both BYD and Tesla have become serious global manufacturers of electric vehicles (EV) worldwide.

With U.S. fintech patent approval, accreditation, and protection for 20 years, our AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors worldwide.

We build, design, and delve into our new and non-obvious proprietary algorithmic system for smart asset return prediction and fintech network platform automation. Unlike our fintech rivals and competitors who chose to keep their proprietary algorithms in a black box, we open the black box by providing the free and complete disclosure of our U.S. fintech patent publication. In this rare unique fashion, we help stock market investors ferret out informative alpha stock signals in order to enrich their own stock market investment portfolios. With no need to crunch data over an extensive period of time, our freemium members pick and choose their own alpha stock signals for profitable investment opportunities in the U.S. stock market.

Smart investors can consult our proprietary alpha stock signals to ferret out rare opportunities for transient stock market undervaluation. Our analytic reports help many stock market investors better understand global macro trends in trade, finance, technology, and so forth. Most investors can combine our proprietary alpha stock signals with broader and deeper macrofinancial knowledge to win in the stock market.

Through our proprietary alpha stock signals and personal finance tools, we can help stock market investors achieve their near-term and longer-term financial goals. High-quality stock market investment decisions can help investors attain the near-term goals of buying a smartphone, a car, a house, good health care, and many more. Also, these high-quality stock market investment decisions can further help investors attain the longer-term goals of saving for travel, passive income, retirement, self-employment, and college education for children. Our AYA fintech network platform empowers stock market investors through better social integration, education, and technology.

The global market for GLP-1 weight-loss medications can grow substantially to benefit more than 1 billion people worldwide by 2030. - Blog - AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors.

The global market for GLP-1 anti-obesity weight-loss medications remains in a rare unique situation ...

https://ayafintech.network/blog/the-global-market-for-GLP-1-weight-loss-medications-grows-substantially-to-benefit-1-billion-people-worldwide-by-2030/

Apple Boston

2025-05-14 03:30:04

Bullish

Quantitative fundamental analysis

Our new podcast deep-dives into how today tech titans, billionaires, serial entrepreneurs, and venture capitalists continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

$MRK $PFE $JNJ $BMY $GSK $NVO $LLY $BNT $MRNA $AZN $AMGN $IONQ $QUBT $QBTS $RGTI $C 

$BAC $WFC $JPM $MS $GS $PNC $V $MA $AXP $PLTR $PYPL $ZIM $T $TMUS $VZ $CMCSA $WMT $HD 

$PG $TGT $COST $IBM $ARM $ORCL $CSCO $SNPS $NET $CRWD $SNOW $AMC $AEO $TSM $NIO 




This fun podcast is about 10 minutes long (with smart AI podcast generation from Google NotebookLM). https://bit.ly/41KDNLp

We discuss, describe, and delve into the new medical sciences of longer longevity and their broader implications for stock market investments. In our modern human history since 1950, the average life expectancy worldwide has incrementally risen by 3 months to 5 months each year. The vast majority of men and women can now expect to live well beyond 70 years in many of the rich countries. This demographic mega trend reflects new medications, treatments, and therapies for many common diseases, disorders, symptoms, and other health conditions in association with old age. These diseases, disorders, and other health conditions include heart diseases, diabetes, Alzheimer’s and Parkinson’s diseases, sleep apnea and other disorders, peripheral arterial diseases, liver and kidney diseases, some sorts of cancers, non-alcoholic steato-hepatitis, knee osteoarthritis, and so forth. Many tech titans have invested heavily on high-efficacy medications, treatments, and therapies for these diseases, disorders, and other health conditions in support of both longer lifespan and substantial improvements in the health quality of life.

However, there are at least 2 major caveats. First, the increases in human lifespan are only incremental and so eventually confront the upper limit. Although the global number of centenarians continues to grow over time, this number seems to stretch its limit in due course. A recent Pew Research survey shows the new projection of more than 3.7 million centenarians worldwide by 2050, or almost 3 times as many centenarians per head of population as in 2015. Nonetheless, only one in 1,000 of these centenarians can live beyond 110 years, and almost no one can live beyond 120 years in modern human history. The maximum human age seems to rise at a much slower pace than the average human life expectancy does in recent decades. Second, the average healthspan, or the number of healthy vital years, may or may not keep pace with longer lifespan. For this reason, many tech titans have invested heavily in modern AI technological advancements in new medications, treatments, and therapies to support both longer lifespan and substantial health improvements in the quality of life for many men and women worldwide. Further, pharmaceutical titans have invested significantly in brand-new third-generation anti-obesity weight-loss medications primarily due to their increasingly higher efficacy and other health benefits. As many men and women now live longer lives, longer lifespan reflects a mix of clean, lean, and healthy lifestyle changes, choices, and decisions from good diet and regular exercise to smarter and better sleep, mood control, less or minimal stress, and deeper, greater, and broader social integration with family and friends. Today, new biomedical innovations, research endeavors, and capital investments help slow down and even reverse human age progression.

Several stock market magnates, moguls, tycoons, and key venture capitalists have been instrumental in the creation of lean startups in support of both longer lifespan and better healthspan. For instance, the serial venture capitalist and co-founder of PayPal and Facebook etc, Peter Thiel, invested a hard, high, and hefty fraction of his personal net worth in many medtech advances and lean startups in health care, precision medicine, and biotechnology. These ventures include Palantir, Women’s Healthcare Fund, Founders Fund, and Lindus Health. Specifically, Thiel invested more than $410 million in a strategic partnership between Palantir and the British National Health Service (NHS) to completely revamp the NHS patient data system. In addition, Thiel supported Recharge Capital’s $200 million Women’s Healthcare Fund to focus on high-efficacy alternative medications, treatments, and therapies for breast cancer, endometriosis, and polycystic ovary syndrome (PCOS). Through Founders Fund, Thiel invested many millions of dollars in 5 major lean startups for better biotech and medtech advances, inventions, and solutions. These major lean startups span Forward Health, Emerald, Cambrian, Counsyl, and Stemcentrx (now as part of AbbVie). In the meantime, these ventures focus on the new, non-obvious, and next-generation technical advances and medical innovations in biometric body scans, blood tests, stem cell therapies, and genetic modifications for better disease prevention. In recent years, Thiel contributed to the $6 million venture investment fund for the London company, Lindus Health, to dramatically speed up clinical trials for new medications, treatments, and therapies.

The Stanford co-founders of Google, Larry Page and Sergey Brin, invested heavily in better biotech, healthcare, and precision medicine too, primarily through 2 major Alphabet subsidiaries Verily and Calico. Today, Verily focuses on new medications, treatments, and therapies for dyspraxia, dyslexia, sleep apnea, insomnia, anxiety, depression, and other mental health and movement disorders. Furthermore, Verily seeks to eradicate all sorts of infectious diseases by killing insects and mosquitoes with the Zika, dengue fever, and other viruses and bacteria etc. In addition, Google DeepMind applies machine-learning algorithms and other AI-driven instruments to substantially sharpen the medical predictions of fatal diseases such as kidney and liver failures, stroke, cardiac arrest, sepsis, and pulmonary embolism.

Google DeepMind has built a new program, AlphaFold, from the previous success of AlphaGo in outperforming the top Go chess players worldwide. With AlphaFold, biomedical scientists help accelerate the major identification of new compounds in better clinical trials. Specifically, AlphaFold analyzes how some sequence of amino acids folds into the particular shape for some sort of protein. In essence, AlphaFold helps identify the more complex set of rules for some sequence of amino acids to fold biomedically into the same shape for some sort of protein in the human body. With tremendous success worldwide, AlphaFold accelerates and so revolutionizes the new wave of innovative drug discovery in support of smarter, faster, and better AI-driven medications, treatments, and therapies. In 2024, Google DeepMind CEO and Co-Founder Sir Demis Hassabis and DeepMind Director Dr John Jumper won the Nobel Prize in Chemistry for their recent design and development of AlphaFold for predicting the structures of different proteins from their amino acid sequences. Hassabis and Jumper shared this Nobel Prize with Dr David Baker who worked on computational protein design.

Many clever biomedical scientists had been trying hard to create computer models of the structural processes for folding amino acids into proteins in the human body for many decades. Just as AlphaGo trounced the best Go chess human players in recent years, AlphaFold substantially improved the best efforts of many biomedical scientists in past decades. Specifically, the shape of each protein reveals immense practical importance in terms of what the protein does alone, what other molecules can do to this protein, and the complex chemical interactions between each protein itself and its nearby and adjacent molecules and chains of amino acids. Almost all the basic structural processes of life depend on new complex chemical interactions among vital proteins, molecules, amino acid chains, and so forth. The vast majority of new drug discovery programs aim to find some sorts of molecules in support of desirable chemical interactions. Sometimes these molecules block specific protein actions, and sometimes these molecules encourage and stimulate specific protein actions. Before AlphaFold, more than 50 years of structural biology had produced several hundred thousand reliable protein structures through the traditional X-rays and nuclear-magnetic resonance techniques. AlphaFold and its closest rivals and competitors, ESMFold by Meta AI, OmegaFold by Helixon, and RoseTTAFold by Baker Lab, have provided more than 600 million sharp and accurate predictions of protein shapes for AI-driven medications, treatments, and therapies. Today, these deep machine-learning algorithms and Gen AI models, robots, and instruments etc continue to accelerate new technological advancements in structural biology.

Nowadays, Larry Page and Sergey Brin drive and steer Calico’s scientific research endeavors to build up new longitudinal patient databases. The next steps can help reveal the mainstream medical mechanisms for human age progression. In close collaboration with top institutions such as Harvard Medical School and Mayo Clinic, Calico delves into how biomedical doctors, scientists, and other health specialists can use new medications, treatments, and therapies to help slow down the natural course of human age progression. Today, the Food and Drug Administration (FDA) still does not recognize old age as a disease state and therefore as a proper target for treatment in America. Despite this current obstacle, Calico now navigates many health factors, forces, and biochemical interactions for medical intervention. These best efforts can combine to help each patient return to the new normal steady state. Even though these best efforts cannot reverse human age progression, these best efforts can perhaps help extend human healthspan dramatically in due course.

The founder and serial entrepreneur of Amazon, Jeff Bezos, invested in numerous companies in support of early cancer detection (Grail), immunotherapy (Juno), and anti-aging research (Unity) primarily through his venture fund, Bezos Expeditions. In recent years, the CEO and co-founder of OpenAI, Sam Altman, backed the $1 billion round for the AI-driven healthcare startup, Retro Biosciences, in support of new medications, treatments, and therapies for common diseases, disorders, and other health ailments. Through the Gates Foundation, Bill Gates invested heavily in new high-efficacy medications, vaccines, treatments, therapies, and healthcare services worldwide. Specifically, the Gates Foundation provides a $90 million prize for the new, non-obvious, next-generation pneumococcal conjugate vaccine (PCV). In accordance with the original prize proposal by Nobel Laureate Michael Kremer, the Gates Foundation strives to prevent pneumococcal infections by providing the new vaccine to each person at the $2.00 marginal cost. In recent years, the Gates Foundation continues to finance global biomedical research programs to eradicate HIV-AIDS, tuberculosis, polio, and malaria, especially in sub-Saharan Africa. With Quantum Biosciences, the Gates Foundation now aims to advance mRNA vaccine design, research, and mass production for efficient Covid prevention. Through the Dementia Discovery Fund, Bill Gates supports many lean-startup ventures on new medications and treatments for Alzheimer’s and Parkinson’s diseases. In addition, Gates continues to finance Foundation Medication in support of the new discovery of DNA sequences for cancer medications. Today, Bill Gates serves as one of the major investors in Ginkgo Bioworks. This biotech company helps tailor biochemical health products and medications to men and women with specific DNA sequences. We believe these resultant biomedical research developments can come to fruition in due course.

Beneath the forest canopy of pharmaceutical titans and startups with tech royalty, an undergrowth of lean startups continues to work on new medications, treatments, and therapies against some aspects of human age progression. The basic insight catches on of prolonging both lifespan and healthspan with some pills and potions, in addition to the more conventional baseline approach of diet, exercise, and high-quality sleep. New diagnostic tools, machines, and instruments provide the means for biomedical scientists to calculate the biological ages of both bodies and organs by comparison to actual calendar ages. In principle, this new capability allows both lifespan and healthspan studies to attain remarkable results in less than a lifetime. New gene modifications further help analyze vast amounts of gene sequence data. This new capability helps personalize new stem cells, medications, and treatments with a broader menu of therapeutic options.

Unlike many machines, bodies both make themselves and repair themselves. Why do human bodies age progressively with so many imperfections? Perhaps the high designer of life, natural evolution, focuses on better reproduction instead of longer lifespan. Life arises as a result of genes, development, behavior, and the broader environment. With accidents, predators, and diseases, the environment kills many creatures. Genes with health benefits that show up only over a longer lifespan than the broader environment allows in practice are not likely to perform particularly well in reproduction unless these genes provide some other health benefits. Genes that provide a fertile youth with successful reproduction are often onto a winner. There is some evidence that one variant of a specific gene in association with Alzheimer’s and Parkinson’s diseases provides reproductive advantages to young people.

From the evolutionary point of view of the genes, a person is a way to make further copies of the genes. In this wider view, a person’s life is a means to an end but not an end in itself. Keeping the human body’s repair mechanisms in tip-top conditions is worthwhile only if the human body gets more genes into the next generation. In this disposable soma approach, the person is a means to an end, and we abandon the life if it is no longer fit for the mainstream purpose of reproduction. This broader perspective helps explain why many diseases and other health conditions are often common in old age but relatively rare in early life. These diseases and other health conditions include Alzheimer’s and Parkinson’s diseases, diabetes, heart diseases, some sorts of cancers, retinal degeneration, osteoarthritis, and so forth.

Many genes have variants, also known as alleles, and all of these alleles work but may cause slightly different effects. With the genetic manipulation of lab organisms, some studies of the genes of human centenarians have identified alleles of specific genes that have been proven experimentally to prolong lifespan. These genes also result in significant improvements in the health quality of life. In recent years, these new studies can often help illuminate the natural course of human age progression. In recent years, these new studies suggest 12 hallmarks of human age progression. The dirty dozen spans genomic instability, telomere attrition, epigenetic alteration, metabolic decline for nutrient energy, mitochondrion dysfunction, proteostasis loss, stem cell exhaustion, chronic inflammation, autophagy decline, dysbiosis, cellular senescence, and intercellular breakdown. We delve into the mainstream scientific progress on each of these 12 hallmarks of human age progression. The devil is in the detail. Biomedicine can be quite complex. Sometimes a biomedical intervention may perform well in more than one field. At other times, there may be trade-offs in new medications, treatments, and therapies. We discuss, describe, and delve into the biomedical sciences of both longer lifespan and smarter and better healthspan, as well as their broader implications for stock market investments.

Below we provide hyperlinks to many other recent podcasts and articles on global macro-finance, asset return prediction, and fundamental industry analysis for stock market investors.

American exceptionalism often turns out to be the heuristic rule of thumb for better economic growth, low and stable inflation, full employment, and macro-financial stability.

In the broader modern monetary policy context, central banks learn to weigh the trade-offs between output and inflation expectations and macro-financial stress conditions.

Today, tech titans, billionaires, serial entrepreneurs, and venture capitalists continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

Artificial intelligence continues to reshape the current global market for better biotech advances, medical innovations, and healthcare services.

The global market for GLP-1 anti-obesity weight-loss treatments now grows substantially to benefit more than 1 billion people worldwide by 2030.

Is higher stock market concentration good or bad for Corporate America?

Geopolitical alignment often reshapes and reinforces asset market fragmentation in the broader context of financial deglobalization.

The global cloud infrastructure helps accelerate the next high-tech revolutions in electric vehicles (EV), virtual reality (VR) headsets, artificial intelligence (AI) online services, and the metaverse.

The new homeland industrial policy stance tilts toward greater global resilience across the major high-tech supply chains worldwide.

China poses new threats to the U.S. and its western allies.

How can generative AI tools and LLMs help enhance human productivity?

What are the macrofinancial ripple effects of central bank digital currency (CBDC) design, issuance, and broad user adoption?

Both BYD and Tesla have become serious global manufacturers of electric vehicles (EV) worldwide.

With U.S. fintech patent approval, accreditation, and protection for 20 years, our AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors worldwide.

We build, design, and delve into our new and non-obvious proprietary algorithmic system for smart asset return prediction and fintech network platform automation. Unlike our fintech rivals and competitors who chose to keep their proprietary algorithms in a black box, we open the black box by providing the free and complete disclosure of our U.S. fintech patent publication. In this rare unique fashion, we help stock market investors ferret out informative alpha stock signals in order to enrich their own stock market investment portfolios. With no need to crunch data over an extensive period of time, our freemium members pick and choose their own alpha stock signals for profitable investment opportunities in the U.S. stock market.

Smart investors can consult our proprietary alpha stock signals to ferret out rare opportunities for transient stock market undervaluation. Our analytic reports help many stock market investors better understand global macro trends in trade, finance, technology, and so forth. Most investors can combine our proprietary alpha stock signals with broader and deeper macrofinancial knowledge to win in the stock market.

Through our proprietary alpha stock signals and personal finance tools, we can help stock market investors achieve their near-term and longer-term financial goals. High-quality stock market investment decisions can help investors attain the near-term goals of buying a smartphone, a car, a house, good health care, and many more. Also, these high-quality stock market investment decisions can further help investors attain the longer-term goals of saving for travel, passive income, retirement, self-employment, and college education for children. Our AYA fintech network platform empowers stock market investors through better social integration, education, and technology.

Today, tech titans continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan. - Blog - AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors.

This report delves into how today tech titans, billionaires, and venture capitalists continue to res...

https://ayafintech.network/blog/today-tech-titans-reshape-global-pharmaceutical-investments-for-both-better-healthspan-and-longer-lifespan/

Monica McNeil

2025-05-10 05:36:45

Bullish

Quantitative fundamental analysis

Our latest podcast deep-dives into how artificial intelligence continues to reshape the current global market for better biotech advances, medical innovations, and healthcare services. Specifically, AlphaFold analyzes how some sequence of amino acids folds into the particular shape for some sort of protein. In essence, AlphaFold helps identify the more complex set of rules for some sequence of amino acids to fold biomedically into the same shape for some sort of protein in the human body.


$MRK $PFE $MRNA $JNJ $BMY $BNT $LLY $ABBV $SDGR $NVO $AMGN $META $GOOG $GOOGL $C 

$AMZN $AAPL $MSFT $NVDA $TSM $AMD $ARM $AVGO $QCOM $ORCL $CSCO $IBM $CRWD $NET 

$SNPS $IONQ $ZIM $COST $WMT $TGT $PG $HD $HPE $QUBT $QBTS $RGTI $JPM $BAC $WFC $MA 


#accrual #issuance #residualvariance #returnvariance #shortreversal #longreversal #murphyrank #bollinger 

With tremendous success worldwide, AlphaFold accelerates and so revolutionizes the new wave of innovative drug discovery in support of smarter, faster, and better AI-driven medications, treatments, and therapies. In 2024, Google DeepMind CEO and Co-Founder Sir Demis Hassabis and DeepMind Director Dr John Jumper won the Nobel Prize in Chemistry for their recent design and development of AlphaFold for predicting the structures of different proteins from their amino acid sequences. Hassabis and Jumper shared this Nobel Prize with Dr David Baker who worked on computational protein design.


This fun podcast is about 10 minutes long (with smart AI podcast generation from Google NotebookLM). https://bit.ly/4hBVimM

As medical doctors, surgeons, and physicians now integrate artificial intelligence (AI) into the mainstream technological advancements in better biotech, healthcare, and medicine, this integration helps reshape the competitive landscape worldwide. We can identify several mega trends for AI-driven better biotech advances, health-care services, and medical innovations. First, some recent AI-driven technological advancements help enhance diagnostic accuracy, improve patient health results, and personalize treatment plans. For instance, deep machine-learning algorithms help develop custom cancer therapies, target medications, and pharmacogenomic treatments in accordance with individual genetic and biochemical profiles. Second, the global pharmaceutical sector benefits substantially from Generative AI (Gen AI) with more than $100 billion AI-driven worldwide sales for new medications. These new medications help cure heart diseases, peripheral arterial diseases, diabetes, sleep apnea and other sleep disorders, some sorts of cancers, chronic kidney and liver diseases, non-alcoholic steato-hepatitis, knee osteoarthritis, and so forth. This broader macro shift highlights the increasingly vital dependence on Gen AI for drug discovery. With AlphaFold, biomedical scientists accelerate the major identification of new compounds for optimal clinical trials. Third, AI helps develop fresh personal treatment plans in response to the unique needs of individual patients with higher efficacy and tolerance. This development often helps better manage rare diseases, complex conditions, side-effects, and even contraindications. AI can analyze large amounts of data to recommend better target therapies. Fourth, AI technology helps integrate new diagnostic machines and devices, surgical robots, medications, and other medical innovations into the broader patient care system. These AI advances often support substantial improvements in the quality of life for the average patient. Further, new AI predictive analytics help identify potential health issues, symptoms, diseases, disorders, and complications. In effect, these new AI predictive analytics allow for proactive biomedical interventions in time. Finally, AI technology can help alleviate increasingly severe global healthcare challenges such as longer longevity, obesity, and urbanization. These new broader demographic shifts seem to present additional opportunities and challenges for many mainstream AI-driven healthcare systems worldwide.

We delve into the 4 major fundamental forms of AI integration in the global market for better biotech advances, medical innovations, and healthcare services. Doctors leverage AI-driven diagnostic devices, machines, and instruments to better inform medical decisions. This leverage is quite important today because almost 800,000 Americans suffer from bad medical decisions each year. Also, many patients seek sound professional medical assistance with their symptoms, side-effects, diseases, disorders, complications, and other health issues etc. Further, AI-driven smart data analytics help accelerate scientific research endeavors in support of smarter, faster, and better medical treatments. Moreover, new AI data analytics help promote more fierce competition in each of the major medical fields, domains, and specialties. In time, the resultant pervasive rise in global market competition likely leads to more cost-effective medications, treatments, and therapies etc. New AI technology helps hospitals, clinics, and health care centers modernize the diagnostic devices, robots, instruments, and even perhaps central command dashboards for the more efficient allocation of both public and private health care resources. Specifically, some new surveys estimate a common shortage of 10 million healthcare workers by 2030, or almost 15% of total healthcare workers worldwide today. Many governments seek to apply AI technological advances more broadly to help bridge the key shortfall of healthcare workers worldwide.

Below we provide hyperlinks to many other recent podcasts and articles on global macro-finance, asset return prediction, and fundamental industry analysis for stock market investors.

American exceptionalism often turns out to be the heuristic rule of thumb for better economic growth, low and stable inflation, full employment, and macro-financial stability.

In the broader modern monetary policy context, central banks learn to weigh the trade-offs between output and inflation expectations and macro-financial stress conditions.

Today, tech titans, billionaires, serial entrepreneurs, and venture capitalists continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

Artificial intelligence continues to reshape the current global market for better biotech advances, medical innovations, and healthcare services.

The global market for GLP-1 anti-obesity weight-loss treatments now grows substantially to benefit more than 1 billion people worldwide by 2030.

Is higher stock market concentration good or bad for Corporate America?

Geopolitical alignment often reshapes and reinforces asset market fragmentation in the broader context of financial deglobalization.

The global cloud infrastructure helps accelerate the next high-tech revolutions in electric vehicles (EV), virtual reality (VR) headsets, artificial intelligence (AI) online services, and the metaverse.

The new homeland industrial policy stance tilts toward greater global resilience across the major high-tech supply chains worldwide.

China poses new threats to the U.S. and its western allies.

How can generative AI tools and LLMs help enhance human productivity?

What are the macrofinancial ripple effects of central bank digital currency (CBDC) design, issuance, and broad user adoption?

Both BYD and Tesla have become serious global manufacturers of electric vehicles (EV) worldwide.

With U.S. fintech patent approval, accreditation, and protection for 20 years, our AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors worldwide.

We build, design, and delve into our new and non-obvious proprietary algorithmic system for smart asset return prediction and fintech network platform automation. Unlike our fintech rivals and competitors who chose to keep their proprietary algorithms in a black box, we open the black box by providing the free and complete disclosure of our U.S. fintech patent publication. In this rare unique fashion, we help stock market investors ferret out informative alpha stock signals in order to enrich their own stock market investment portfolios. With no need to crunch data over an extensive period of time, our freemium members pick and choose their own alpha stock signals for profitable investment opportunities in the U.S. stock market.

Smart investors can consult our proprietary alpha stock signals to ferret out rare opportunities for transient stock market undervaluation. Our analytic reports help many stock market investors better understand global macro trends in trade, finance, technology, and so forth. Most investors can combine our proprietary alpha stock signals with broader and deeper macrofinancial knowledge to win in the stock market.

Through our proprietary alpha stock signals and personal finance tools, we can help stock market investors achieve their near-term and longer-term financial goals. High-quality stock market investment decisions can help investors attain the near-term goals of buying a smartphone, a car, a house, good health care, and many more. Also, these high-quality stock market investment decisions can further help investors attain the longer-term goals of saving for travel, passive income, retirement, self-employment, and college education for children. Our AYA fintech network platform empowers stock market investors through better social integration, education, and technology.

In the current global market for better biotech advances, medical innovations, and healthcare services, the new integration of artificial intelligence (AI) reshapes the competitive landscape worldwide. - Blog - AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors.

AI-driven advances help reshape the competitive landscape for new medications, treatments, therapies...

https://ayafintech.network/blog/the-new-integration-of-artificial-intelligence-reshapes-the-competitive-landscape-for-the-global-market-for-better-medical-innovations-and-healthcare-services/\nThis

Monica McNeil

2025-05-03 03:46:11

Bullish

Quantitative fundamental analysis

Our latest podcast deep-dives into the stock market implications of financial deglobalization in recent years. Geopolitical alignment often reshapes and reinforces asset market fragmentation in the broader context of financial deglobalization.


$META $AAPL $MSFT $AMZN $GOOG $GOOGL $NVDA $TSLA $TSM $AMD $QCOM $AMD $IBM $CSCO 

$BABA $BIDU $TME $BILI $JD $PDD $IQ $NIO $KKR $ORCL $NET $CRWD $SNOW $SNPS $AMC $PARA 

$BAC $WFC $JPM $MS $GS $C $V $MA $AXP $PNC $PYPL $PLTR $HPE $PFE $COST $WMT $HD $TGT 

$PG $KO $IONQ $ZIM $MAC $JNJ $MRK $BMY $LLY $MRNA $BNT $GSK $HP $RACE $QUBT $QBTS $T 


#issuance #accrual #shortreversal #longreversal #residualvariance #returnvariance #fibonacci #murphyrank 

The original blog article is available on our AYA fintech network platform.

This fun podcast is about 10 minutes long (with smart AI podcast generation from Google NotebookLM). https://bit.ly/3ZpGMcD

We delve into the mainstream public policy implications of financial deglobalization in recent years. The U.S. and its western allies impose some economic sanctions on global trade and finance in relation to China, Russia, Iran, and North Korea. In addition to these sanctions, hefty tariffs, embargoes, and foreign investment bans and restrictions further limit the macrofinancial clout of these countries. As the U.S. and its western allies cut off favorable trade relations with China, Russia, Iran, and North Korea, the current Russia-Ukraine war, the potential invasion of Taiwan by China, the relentless conflict between Israel and Hamas and the Palestinians, and several other geopolitical tensions exacerbate recent asset market fragmentation in the broader context of financial deglobalization. Even though the American dollar remains the dominant global reserve currency and global supply chains prove to be more resilient, global capital flows start to fragment in different directions in the particular context of financial deglobalization. The postwar world order of free trade continues to fall apart at a relatively slow and gradual pace.

The postwar global institutions that safeguard the old world order of free trade are either already defunct or deficient with a lack of longer-term credible commitments these days. The World Trade Organization (WTO) turns 30 in 2025, but continues to have spent more than 5 years in stasis due to western neglect. The World Bank seems to be caught between fighting world poverty and enriching the upper social echelon in new market economies with higher population dividends such as China, Brazil, India, Indonesia, and the Philippines. The International Monetary Fund (IMF) confronts its identity crisis and remains stuck in the middle between global financial stability and green finance in support of better climate risk management worldwide. The World Health Organization (WHO) now needs to cope with the post-pandemic public health risks and threats worldwide, such as new variants of the corona virus. In recent years, the U.N. security council fails to secure world peace and prosperity due to the Russia-Ukraine war in Eastern Europe, the relentless conflict between Israel and Iran, Hamas, and the Palestinians, as well as the recurrent flash points in the North Korean peninsula, Taiwan, South China Sea, and wider Pacific Ocean. The International Court of Justice attempts to weaponize the U.S. and its western allies by issuing arrest warrants for President Vladimir Putin and others who launch wars against humanity, but the Court has little jurisdiction over Russia and Ukraine in Eastern Europe, the Gaza Strip in Middle East, and the Pacific first island chain from the North Korean peninsula and Japan to Taiwan and the Philippines.

The resultant fragmentation of free markets in new democracies imposes a stealth tax on the global economy, in the form of higher inflation or lower purchasing power for each marginal dollar. Unfortunately, human history shows that deeper financial deglobalization may inadvertently worsen the current tilt toward secular stagnation worldwide. Today, a similar rupture seems all too imaginable. The return of Donald Trump to the White House, with his zero-sum worldview, would probably continue the gradual and recurrent erosion of global institutions, norms, and principles all in support of both free trade and democratic capitalism. The far-flung fear of a second wave of low-cost imports from China would likely accelerate this global trend. Any outright war between America and China over Taiwan, or between the NATO and Russia, would further cause an almighty collapse of the world trade system.

Nowadays, it is fashionable for economists to criticize free-market globalization as the root cause of social disparities in wealth and income worldwide, global financial imbalances, as well as climate change risks (even the increasingly hefty economic costs of rare extreme weather events). However, the free trade achievements from the 1990s to the early-2000s help mark the high point of liberal capitalism and then continue to be a rare, unique, and inimitable episode of human history. Through a free ride on the transition to new market economies, China, Brazil, India, Indonesia, and the Philippines integrated into the world economy. As a result, many hundreds of millions escaped poverty. Also, the current infant mortality rate worldwide is less than half what the rate was back in the 1990s, due to greater clean water and food. The proportion of global deaths due to inter-state wars and conflicts has hit a post-war low, less than a thousandth of 0.2% today, down from almost 40 times as high more than 50 years ago. Today, many leaders and politicians hope to replace the old Washington consensus on free trade and market capitalism. The Washington consensus depicts a world economy where poor countries enjoy capital spending booms to catch up on economic growth and employment with rich countries. Due to economic and non-economic risks and issues such as climate change, extreme weather, pandemic disease control, credit contagion, and nuclear proliferation etc, many leaders and politicians attempt to close the economic gap between rich and poor countries through alternative means of trade, finance, and technology.

Indeed, the postwar world order of free trade achieved a merry marriage between the U.S. peace principles and strategic interests. At the same time, this new liberal world order further brought real economic benefits to the rest of the world. In some parts of the world, however, poor residents continue to suffer from the World Bank and IMF’s inability to resolve the sovereign debt crisis after the Covid-19 pandemic years. Several middle-income countries such as India and Indonesia hope to trade their way to riches, but these countries end up trying to exploit free-trade loopholes and opportunities due to financial deglobalization and asset market fragmentation. In practice, the global economy should remain robust, resilient, and predictable in integrating most prior trade blocs and regions into the new world order of fair trade. In due course, the fair-trade integration helps ensure global peace and prosperity with the long prevalent American-driven institutions, norms, and principles in favor of free-market capitalism, democratization, and the lofty pursuit of a good life.

Below we provide hyperlinks to many other recent podcasts and articles on global macro-finance, asset return prediction, and fundamental industry analysis for stock market investors.

American exceptionalism often turns out to be the heuristic rule of thumb for better economic growth, low and stable inflation, full employment, and macro-financial stability.

In the broader modern monetary policy context, central banks learn to weigh the trade-offs between output and inflation expectations and macro-financial stress conditions.

Today, tech titans, billionaires, serial entrepreneurs, and venture capitalists continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

Artificial intelligence continues to reshape the current global market for better biotech advances, medical innovations, and healthcare services.

The global market for GLP-1 anti-obesity weight-loss treatments now grows substantially to benefit more than 1 billion people worldwide by 2030.

Is higher stock market concentration good or bad for Corporate America?

Geopolitical alignment often reshapes and reinforces asset market fragmentation in the broader context of financial deglobalization.

The global cloud infrastructure helps accelerate the next high-tech revolutions in electric vehicles (EV), virtual reality (VR) headsets, artificial intelligence (AI) online services, and the metaverse.

The new homeland industrial policy stance tilts toward greater global resilience across the major high-tech supply chains worldwide.

China poses new threats to the U.S. and its western allies.

How can generative AI tools and LLMs help enhance human productivity?

What are the macrofinancial ripple effects of central bank digital currency (CBDC) design, issuance, and broad user adoption?

Both BYD and Tesla have become serious global manufacturers of electric vehicles (EV) worldwide.

With U.S. fintech patent approval, accreditation, and protection for 20 years, our AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors worldwide.

We build, design, and delve into our new and non-obvious proprietary algorithmic system for smart asset return prediction and fintech network platform automation. Unlike our fintech rivals and competitors who chose to keep their proprietary algorithms in a black box, we open the black box by providing the free and complete disclosure of our U.S. fintech patent publication. In this rare unique fashion, we help stock market investors ferret out informative alpha stock signals in order to enrich their own stock market investment portfolios. With no need to crunch data over an extensive period of time, our freemium members pick and choose their own alpha stock signals for profitable investment opportunities in the U.S. stock market.

Smart investors can consult our proprietary alpha stock signals to ferret out rare opportunities for transient stock market undervaluation. Our analytic reports help many stock market investors better understand global macro trends in trade, finance, technology, and so forth. Most investors can combine our proprietary alpha stock signals with broader and deeper macrofinancial knowledge to win in the stock market.

Through our proprietary alpha stock signals and personal finance tools, we can help stock market investors achieve their near-term and longer-term financial goals. High-quality stock market investment decisions can help investors attain the near-term goals of buying a smartphone, a car, a house, good health care, and many more. Also, these high-quality stock market investment decisions can further help investors attain the longer-term goals of saving for travel, passive income, retirement, self-employment, and college education for children. Our AYA fintech network platform empowers stock market investors through better social integration, education, and technology.

Geopolitical alignment often reshapes and reinforces asset market fragmentation in the broader context of financial deglobalization. - Blog - AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors.

Geopolitical alignment often reshapes and reinforces asset market fragmentation in the broader conte...

https://ayafintech.network/blog/geopolitical-alignment-often-reshapes-and-reinforces-asset-market-fragmentation-in-the-broader-context-of-financial-deglobalization/\nThis

Chanel Holden

2025-05-01 11:08:03

Bullish

Quantitative fundamental analysis

Our latest podcast deep-dives into the technological advancements in cloud services. The global cloud infrastructure helps accelerate the next high-tech revolutions in electric vehicles (EV), virtual reality (VR) headsets, artificial intelligence (AI) online services, and the metaverse.


$META $AAPL $MSFT $AMZN $GOOG $GOOGL $NVDA $TSLA $TSM $ARM $QCOM $AVGO $AMD $IONQ 

$ASML $CSCO $SNPS $IBM $NET $CRWD $SNOW $COST $WMT $TGT $HD $PG $V $MA $AXP $BABA 

$BIDU $TME $JD $PDD $IQ $BILI $KKR $AMC $PARA $NFLX $DIS $WRB $PYPL $PLTR $ZIM $PFE $MRK 


#residualvariance #returnvariance #fibonacci #murphyrank #bollinger #shortreversal #longreversal #issuance 

The original blog article is available on our AYA fintech network platform.

This fun podcast is about 10 minutes long (with smart AI podcast generation from Google NotebookLM). https://bit.ly/47pDk3z

The global market for mobile cloud telecommunication continues to expand into a widespread economic phenomenon. Through the new mobile cloud infrastructure, the Internet broadens and deepens what can be made digitally feasible from virtual reality (VR) headsets and electric vehicles (EV) to artificial intelligence (AI) and the metaverse. In this positive light, the current cloud infrastructure can help facilitate a new wave of digital revolutions worldwide. Underneath all of these layers of cloud abstraction, the Internet infrastructure serves as the new foundation of our chosen digital future. In the broader context of digital technological advancements, we help demystify the physical building blocks of the cloud Internet infrastructure worldwide in order to explain how they mold, shape, expand, and constrain digital abstraction. Now many practical Internet uses multiply far beyond the original remit. Specifically, we delve into what the physical layers of cloud abstraction are likely to change for the Internet to remain sustainable both in the physical sense and in the wider sense of global environmental protection.

From the seabed across the Atlantic and Pacific Oceans to data centers in the key cities on the U.S. West Coast and the East Coast, the fiber-optic cables form the backbone of the physical Internet worldwide. Through the fiber-optic cables, almost all Internet traffic flows back and forth day in and day out. From Apple and Google to Meta, Microsoft, and Amazon, several tech titans vertically integrate the Internet by laying out fiber-optic cables, building out data centers in different countries, and further providing cloud services with AI search engines, robots, avatars, and virtual assistants. As the Internet becomes more powerful, it is vitally important for us to better understand its physical and corporate composition. Only by peeling back the multiple layers of digital abstraction can one lay bare the critical foundations of the new Internet. In the Internet, all technological advancements help support the next dual waves of both business model transformations and digital revolutions around the world. These advancements shine fresh light on how AI-driven cloud services help accelerate the new generation of disruptive innovations in trade, finance, and technology. Every new business can become an AI cloud service provider.

Below we provide hyperlinks to many other recent podcasts and articles on global macro-finance, asset return prediction, and fundamental industry analysis for stock market investors.

American exceptionalism often turns out to be the heuristic rule of thumb for better economic growth, low and stable inflation, full employment, and macro-financial stability.

In the broader modern monetary policy context, central banks learn to weigh the trade-offs between output and inflation expectations and macro-financial stress conditions.

Today, tech titans, billionaires, serial entrepreneurs, and venture capitalists continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

Artificial intelligence continues to reshape the current global market for better biotech advances, medical innovations, and healthcare services.

The global market for GLP-1 anti-obesity weight-loss treatments now grows substantially to benefit more than 1 billion people worldwide by 2030.

Is higher stock market concentration good or bad for Corporate America?

Geopolitical alignment often reshapes and reinforces asset market fragmentation in the broader context of financial deglobalization.

The global cloud infrastructure helps accelerate the next high-tech revolutions in electric vehicles (EV), virtual reality (VR) headsets, artificial intelligence (AI) online services, and the metaverse.

The new homeland industrial policy stance tilts toward greater global resilience across the major high-tech supply chains worldwide.

China poses new threats to the U.S. and its western allies.

How can generative AI tools and LLMs help enhance human productivity?

What are the macrofinancial ripple effects of central bank digital currency (CBDC) design, issuance, and broad user adoption?

Both BYD and Tesla have become serious global manufacturers of electric vehicles (EV) worldwide.

With U.S. fintech patent approval, accreditation, and protection for 20 years, our AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors worldwide.

We build, design, and delve into our new and non-obvious proprietary algorithmic system for smart asset return prediction and fintech network platform automation. Unlike our fintech rivals and competitors who chose to keep their proprietary algorithms in a black box, we open the black box by providing the free and complete disclosure of our U.S. fintech patent publication. In this rare unique fashion, we help stock market investors ferret out informative alpha stock signals in order to enrich their own stock market investment portfolios. With no need to crunch data over an extensive period of time, our freemium members pick and choose their own alpha stock signals for profitable investment opportunities in the U.S. stock market.

Smart investors can consult our proprietary alpha stock signals to ferret out rare opportunities for transient stock market undervaluation. Our analytic reports help many stock market investors better understand global macro trends in trade, finance, technology, and so forth. Most investors can combine our proprietary alpha stock signals with broader and deeper macrofinancial knowledge to win in the stock market.

Through our proprietary alpha stock signals and personal finance tools, we can help stock market investors achieve their near-term and longer-term financial goals. High-quality stock market investment decisions can help investors attain the near-term goals of buying a smartphone, a car, a house, good health care, and many more. Also, these high-quality stock market investment decisions can further help investors attain the longer-term goals of saving for travel, passive income, retirement, self-employment, and college education for children. Our AYA fintech network platform empowers stock market investors through better social integration, education, and technology.

The global cloud expands what can be made digitally viable from electric vehicles (EV) and virtual reality (VR) headsets to artificial intelligence (AI) and the metaverse. - Blog - AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors.

We help demystify the physical building blocks of the Internet infrastructure in order to explain ho...

https://ayafintech.network/blog/the-global-cloud-infrastructure-helps-expand-what-can-be-made-digitally-viable-from-electric-vehicles-and-virtual-reality-headsets-to-artificial-intelligence-metaverse/\nThis

Monica McNeil

2025-03-23 03:41:22

Bullish

Quantitative fundamental analysis

Our latest podcast deep-dives into why, whether, and how today tech titans, billionaires, serial entrepreneurs, and venture capitalists continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.


$GRAL $BMY $UBX $QNTM $DNA $GSK $AZN $BFLY $CLDX $SDGR $NVO $LLY $JNJ $PFE $ABBV 

$MRK $AMGN $UNH $MRNA $T $VZ $TMUS $AEO $AMC $CVS $WMT $TGT $COST $V $MA $AXP 

$MSFT $GOOG $GOOGL $AMZN $AAPL $META $NVDA $TSLA $CSCO $ORCL $IBM $ASML $SNPS 

$NET $CRWD $PARA $NFLX $DIS $BILI $IQ $JD $PDD $BABA $TME $BIDU $BLK $STT $IONQ $C 




This fun podcast is about 10 minutes long (with smart AI podcast generation from Google NotebookLM). https://bit.ly/41KDNLp

We discuss, describe, and delve into the new medical sciences of longer longevity and their broader implications for stock market investments. In our modern human history since 1950, the average life expectancy worldwide has incrementally risen by 3 months to 5 months each year. The vast majority of men and women can now expect to live well beyond 70 years in many of the rich countries. This demographic mega trend reflects new medications, treatments, and therapies for many common diseases, disorders, symptoms, and other health conditions in association with old age. These diseases, disorders, and other health conditions include heart diseases, diabetes, Alzheimer’s and Parkinson’s diseases, sleep apnea and other disorders, peripheral arterial diseases, liver and kidney diseases, some sorts of cancers, non-alcoholic steato-hepatitis, knee osteoarthritis, and so forth. Many tech titans have invested heavily on high-efficacy medications, treatments, and therapies for these diseases, disorders, and other health conditions in support of both longer lifespan and substantial improvements in the health quality of life.

However, there are at least 2 major caveats. First, the increases in human lifespan are only incremental and so eventually confront the upper limit. Although the global number of centenarians continues to grow over time, this number seems to stretch its limit in due course. A recent Pew Research survey shows the new projection of more than 3.7 million centenarians worldwide by 2050, or almost 3 times as many centenarians per head of population as in 2015. Nonetheless, only one in 1,000 of these centenarians can live beyond 110 years, and almost no one can live beyond 120 years in modern human history. The maximum human age seems to rise at a much slower pace than the average human life expectancy does in recent decades. Second, the average healthspan, or the number of healthy vital years, may or may not keep pace with longer lifespan. For this reason, many tech titans have invested heavily in modern AI technological advancements in new medications, treatments, and therapies to support both longer lifespan and substantial health improvements in the quality of life for many men and women worldwide. Further, pharmaceutical titans have invested significantly in brand-new third-generation anti-obesity weight-loss medications primarily due to their increasingly higher efficacy and other health benefits. As many men and women now live longer lives, longer lifespan reflects a mix of clean, lean, and healthy lifestyle changes, choices, and decisions from good diet and regular exercise to smarter and better sleep, mood control, less or minimal stress, and deeper, greater, and broader social integration with family and friends. Today, new biomedical innovations, research endeavors, and capital investments help slow down and even reverse human age progression.

Several stock market magnates, moguls, tycoons, and key venture capitalists have been instrumental in the creation of lean startups in support of both longer lifespan and better healthspan. For instance, the serial venture capitalist and co-founder of PayPal and Facebook etc, Peter Thiel, invested a hard, high, and hefty fraction of his personal net worth in many medtech advances and lean startups in health care, precision medicine, and biotechnology. These ventures include Palantir, Women’s Healthcare Fund, Founders Fund, and Lindus Health. Specifically, Thiel invested more than $410 million in a strategic partnership between Palantir and the British National Health Service (NHS) to completely revamp the NHS patient data system. In addition, Thiel supported Recharge Capital’s $200 million Women’s Healthcare Fund to focus on high-efficacy alternative medications, treatments, and therapies for breast cancer, endometriosis, and polycystic ovary syndrome (PCOS). Through Founders Fund, Thiel invested many millions of dollars in 5 major lean startups for better biotech and medtech advances, inventions, and solutions. These major lean startups span Forward Health, Emerald, Cambrian, Counsyl, and Stemcentrx (now as part of AbbVie). In the meantime, these ventures focus on the new, non-obvious, and next-generation technical advances and medical innovations in biometric body scans, blood tests, stem cell therapies, and genetic modifications for better disease prevention. In recent years, Thiel contributed to the $6 million venture investment fund for the London company, Lindus Health, to dramatically speed up clinical trials for new medications, treatments, and therapies.

The Stanford co-founders of Google, Larry Page and Sergey Brin, invested heavily in better biotech, healthcare, and precision medicine too, primarily through 2 major Alphabet subsidiaries Verily and Calico. Today, Verily focuses on new medications, treatments, and therapies for dyspraxia, dyslexia, sleep apnea, insomnia, anxiety, depression, and other mental health and movement disorders. Furthermore, Verily seeks to eradicate all sorts of infectious diseases by killing insects and mosquitoes with the Zika, dengue fever, and other viruses and bacteria etc. In addition, Google DeepMind applies machine-learning algorithms and other AI-driven instruments to substantially sharpen the medical predictions of fatal diseases such as kidney and liver failures, stroke, cardiac arrest, sepsis, and pulmonary embolism.

Google DeepMind has built a new program, AlphaFold, from the previous success of AlphaGo in outperforming the top Go chess players worldwide. With AlphaFold, biomedical scientists help accelerate the major identification of new compounds in better clinical trials. Specifically, AlphaFold analyzes how some sequence of amino acids folds into the particular shape for some sort of protein. In essence, AlphaFold helps identify the more complex set of rules for some sequence of amino acids to fold biomedically into the same shape for some sort of protein in the human body. With tremendous success worldwide, AlphaFold accelerates and so revolutionizes the new wave of innovative drug discovery in support of smarter, faster, and better AI-driven medications, treatments, and therapies. In 2024, Google DeepMind CEO and Co-Founder Sir Demis Hassabis and DeepMind Director Dr John Jumper won the Nobel Prize in Chemistry for their recent design and development of AlphaFold for predicting the structures of different proteins from their amino acid sequences. Hassabis and Jumper shared this Nobel Prize with Dr David Baker who worked on computational protein design.

Many clever biomedical scientists had been trying hard to create computer models of the structural processes for folding amino acids into proteins in the human body for many decades. Just as AlphaGo trounced the best Go chess human players in recent years, AlphaFold substantially improved the best efforts of many biomedical scientists in past decades. Specifically, the shape of each protein reveals immense practical importance in terms of what the protein does alone, what other molecules can do to this protein, and the complex chemical interactions between each protein itself and its nearby and adjacent molecules and chains of amino acids. Almost all the basic structural processes of life depend on new complex chemical interactions among vital proteins, molecules, amino acid chains, and so forth. The vast majority of new drug discovery programs aim to find some sorts of molecules in support of desirable chemical interactions. Sometimes these molecules block specific protein actions, and sometimes these molecules encourage and stimulate specific protein actions. Before AlphaFold, more than 50 years of structural biology had produced several hundred thousand reliable protein structures through the traditional X-rays and nuclear-magnetic resonance techniques. AlphaFold and its closest rivals and competitors, ESMFold by Meta AI, OmegaFold by Helixon, and RoseTTAFold by Baker Lab, have provided more than 600 million sharp and accurate predictions of protein shapes for AI-driven medications, treatments, and therapies. Today, these deep machine-learning algorithms and Gen AI models, robots, and instruments etc continue to accelerate new technological advancements in structural biology.

Nowadays, Larry Page and Sergey Brin drive and steer Calico’s scientific research endeavors to build up new longitudinal patient databases. The next steps can help reveal the mainstream medical mechanisms for human age progression. In close collaboration with top institutions such as Harvard Medical School and Mayo Clinic, Calico delves into how biomedical doctors, scientists, and other health specialists can use new medications, treatments, and therapies to help slow down the natural course of human age progression. Today, the Food and Drug Administration (FDA) still does not recognize old age as a disease state and therefore as a proper target for treatment in America. Despite this current obstacle, Calico now navigates many health factors, forces, and biochemical interactions for medical intervention. These best efforts can combine to help each patient return to the new normal steady state. Even though these best efforts cannot reverse human age progression, these best efforts can perhaps help extend human healthspan dramatically in due course.

The founder and serial entrepreneur of Amazon, Jeff Bezos, invested in numerous companies in support of early cancer detection (Grail), immunotherapy (Juno), and anti-aging research (Unity) primarily through his venture fund, Bezos Expeditions. In recent years, the CEO and co-founder of OpenAI, Sam Altman, backed the $1 billion round for the AI-driven healthcare startup, Retro Biosciences, in support of new medications, treatments, and therapies for common diseases, disorders, and other health ailments. Through the Gates Foundation, Bill Gates invested heavily in new high-efficacy medications, vaccines, treatments, therapies, and healthcare services worldwide. Specifically, the Gates Foundation provides a $90 million prize for the new, non-obvious, next-generation pneumococcal conjugate vaccine (PCV). In accordance with the original prize proposal by Nobel Laureate Michael Kremer, the Gates Foundation strives to prevent pneumococcal infections by providing the new vaccine to each person at the $2.00 marginal cost. In recent years, the Gates Foundation continues to finance global biomedical research programs to eradicate HIV-AIDS, tuberculosis, polio, and malaria, especially in sub-Saharan Africa. With Quantum Biosciences, the Gates Foundation now aims to advance mRNA vaccine design, research, and mass production for efficient Covid prevention. Through the Dementia Discovery Fund, Bill Gates supports many lean-startup ventures on new medications and treatments for Alzheimer’s and Parkinson’s diseases. In addition, Gates continues to finance Foundation Medication in support of the new discovery of DNA sequences for cancer medications. Today, Bill Gates serves as one of the major investors in Ginkgo Bioworks. This biotech company helps tailor biochemical health products and medications to men and women with specific DNA sequences. We believe these resultant biomedical research developments can come to fruition in due course.

Beneath the forest canopy of pharmaceutical titans and startups with tech royalty, an undergrowth of lean startups continues to work on new medications, treatments, and therapies against some aspects of human age progression. The basic insight catches on of prolonging both lifespan and healthspan with some pills and potions, in addition to the more conventional baseline approach of diet, exercise, and high-quality sleep. New diagnostic tools, machines, and instruments provide the means for biomedical scientists to calculate the biological ages of both bodies and organs by comparison to actual calendar ages. In principle, this new capability allows both lifespan and healthspan studies to attain remarkable results in less than a lifetime. New gene modifications further help analyze vast amounts of gene sequence data. This new capability helps personalize new stem cells, medications, and treatments with a broader menu of therapeutic options.

Unlike many machines, bodies both make themselves and repair themselves. Why do human bodies age progressively with so many imperfections? Perhaps the high designer of life, natural evolution, focuses on better reproduction instead of longer lifespan. Life arises as a result of genes, development, behavior, and the broader environment. With accidents, predators, and diseases, the environment kills many creatures. Genes with health benefits that show up only over a longer lifespan than the broader environment allows in practice are not likely to perform particularly well in reproduction unless these genes provide some other health benefits. Genes that provide a fertile youth with successful reproduction are often onto a winner. There is some evidence that one variant of a specific gene in association with Alzheimer’s and Parkinson’s diseases provides reproductive advantages to young people.

From the evolutionary point of view of the genes, a person is a way to make further copies of the genes. In this wider view, a person’s life is a means to an end but not an end in itself. Keeping the human body’s repair mechanisms in tip-top conditions is worthwhile only if the human body gets more genes into the next generation. In this disposable soma approach, the person is a means to an end, and we abandon the life if it is no longer fit for the mainstream purpose of reproduction. This broader perspective helps explain why many diseases and other health conditions are often common in old age but relatively rare in early life. These diseases and other health conditions include Alzheimer’s and Parkinson’s diseases, diabetes, heart diseases, some sorts of cancers, retinal degeneration, osteoarthritis, and so forth.

Many genes have variants, also known as alleles, and all of these alleles work but may cause slightly different effects. With the genetic manipulation of lab organisms, some studies of the genes of human centenarians have identified alleles of specific genes that have been proven experimentally to prolong lifespan. These genes also result in significant improvements in the health quality of life. In recent years, these new studies can often help illuminate the natural course of human age progression. In recent years, these new studies suggest 12 hallmarks of human age progression. The dirty dozen spans genomic instability, telomere attrition, epigenetic alteration, metabolic decline for nutrient energy, mitochondrion dysfunction, proteostasis loss, stem cell exhaustion, chronic inflammation, autophagy decline, dysbiosis, cellular senescence, and intercellular breakdown. We delve into the mainstream scientific progress on each of these 12 hallmarks of human age progression. The devil is in the detail. Biomedicine can be quite complex. Sometimes a biomedical intervention may perform well in more than one field. At other times, there may be trade-offs in new medications, treatments, and therapies. We discuss, describe, and delve into the biomedical sciences of both longer lifespan and smarter and better healthspan, as well as their broader implications for stock market investments.

With U.S. fintech patent approval, accreditation, and protection for 20 years, our AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors worldwide.

We build, design, and delve into our new and non-obvious proprietary algorithmic system for smart asset return prediction and fintech network platform automation. Unlike our fintech rivals and competitors who chose to keep their proprietary algorithms in a black box, we open the black box by providing the free and complete disclosure of our U.S. fintech patent publication. In this rare unique fashion, we help stock market investors ferret out informative alpha stock signals in order to enrich their own stock market investment portfolios. With no need to crunch data over an extensive period of time, our freemium members pick and choose their own alpha stock signals for profitable investment opportunities in the U.S. stock market.

Smart investors can consult our proprietary alpha stock signals to ferret out rare opportunities for transient stock market undervaluation. Our analytic reports help many stock market investors better understand global macro trends in trade, finance, technology, and so forth. Most investors can combine our proprietary alpha stock signals with broader and deeper macrofinancial knowledge to win in the stock market.

Through our proprietary alpha stock signals and personal finance tools, we can help stock market investors achieve their near-term and longer-term financial goals. High-quality stock market investment decisions can help investors attain the near-term goals of buying a smartphone, a car, a house, good health care, and many more. Also, these high-quality stock market investment decisions can further help investors attain the longer-term goals of saving for travel, passive income, retirement, self-employment, and college education for children. Our AYA fintech network platform empowers stock market investors through better social integration, education, and technology.

Today, tech titans continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan. - Blog - AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors.

This report delves into how today tech titans, billionaires, and venture capitalists continue to res...

https://ayafintech.network/blog/today-tech-titans-reshape-global-pharmaceutical-investments-for-both-better-healthspan-and-longer-lifespan/\nThis

Monica McNeil

2025-03-19 02:05:07

Bullish

Quantitative fundamental analysis

Our latest podcast deep-dives into the AI-driven technological advances for new medications, treatments, therapies, and healthcare services worldwide. With AlphaFold, specifically, biomedical scientists accelerate the major identification of new compounds for better clinical trials. Today, the global pharmaceutical sector benefits substantially from Generative AI (Gen AI) with more than $100 billion AI-driven worldwide sales for new medications.


$BFLY $CLDX $SDGR $NVO $LLY $JNJ $BMY $PFE $ABBV $MRK $AMGN $MRNA $AZN $DOCU $UNH 

$META $MSFT $AMZN $AAPL $GOOG $GOOGL $PYPL $PLTR $WMT $TGT $COST $CVS $AEO $AMC 

$PARA $NFLX $DIS $WRB $V $MA $AXP $T $VZ $TMUS $C $BAC $JPM $WFC $MS $GS $PNC $BLK 




This fun podcast is about 10 minutes long (with smart AI podcast generation from Google NotebookLM). https://bit.ly/4hBVimM

As medical doctors, surgeons, and physicians now integrate artificial intelligence (AI) into the mainstream technological advancements in better biotech, healthcare, and medicine, this integration helps reshape the competitive landscape worldwide. We can identify several mega trends for AI-driven better biotech advances, health-care services, and medical innovations. First, some recent AI-driven technological advancements help enhance diagnostic accuracy, improve patient health results, and personalize treatment plans. For instance, deep machine-learning algorithms help develop custom cancer therapies, target medications, and pharmacogenomic treatments in accordance with individual genetic and biochemical profiles. Second, the global pharmaceutical sector benefits substantially from Generative AI (Gen AI) with more than $100 billion AI-driven worldwide sales for new medications. These new medications help cure heart diseases, peripheral arterial diseases, diabetes, sleep apnea and other sleep disorders, some sorts of cancers, chronic kidney and liver diseases, non-alcoholic steato-hepatitis, knee osteoarthritis, and so forth. This broader macro shift highlights the increasingly vital dependence on Gen AI for drug discovery. With AlphaFold, biomedical scientists accelerate the major identification of new compounds for optimal clinical trials. Third, AI helps develop fresh personal treatment plans in response to the unique needs of individual patients with higher efficacy and tolerance. This development often helps better manage rare diseases, complex conditions, side-effects, and even contraindications. AI can analyze large amounts of data to recommend better target therapies. Fourth, AI technology helps integrate new diagnostic machines and devices, surgical robots, medications, and other medical innovations into the broader patient care system. These AI advances often support substantial improvements in the quality of life for the average patient. Further, new AI predictive analytics help identify potential health issues, symptoms, diseases, disorders, and complications. In effect, these new AI predictive analytics allow for proactive biomedical interventions in time. Finally, AI technology can help alleviate increasingly severe global healthcare challenges such as longer longevity, obesity, and urbanization. These new broader demographic shifts seem to present additional opportunities and challenges for many mainstream AI-driven healthcare systems worldwide.

We delve into the 4 major fundamental forms of AI integration in the global market for better biotech advances, medical innovations, and healthcare services. Doctors leverage AI-driven diagnostic devices, machines, and instruments to better inform medical decisions. This leverage is quite important today because almost 800,000 Americans suffer from bad medical decisions each year. Also, many patients seek sound professional medical assistance with their symptoms, side-effects, diseases, disorders, complications, and other health issues etc. Further, AI-driven smart data analytics help accelerate scientific research endeavors in support of smarter, faster, and better medical treatments. Moreover, new AI data analytics help promote more fierce competition in each of the major medical fields, domains, and specialties. In time, the resultant pervasive rise in global market competition likely leads to more cost-effective medications, treatments, and therapies etc. New AI technology helps hospitals, clinics, and health care centers modernize the diagnostic devices, robots, instruments, and even perhaps central command dashboards for the more efficient allocation of both public and private health care resources. Specifically, some new surveys estimate a common shortage of 10 million healthcare workers by 2030, or almost 15% of total healthcare workers worldwide today. Many governments seek to apply AI technological advances more broadly to help bridge the key shortfall of healthcare workers worldwide.

With U.S. fintech patent approval, accreditation, and protection for 20 years, our AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors worldwide.

We build, design, and delve into our new and non-obvious proprietary algorithmic system for smart asset return prediction and fintech network platform automation. Unlike our fintech rivals and competitors who chose to keep their proprietary algorithms in a black box, we open the black box by providing the free and complete disclosure of our U.S. fintech patent publication. In this rare unique fashion, we help stock market investors ferret out informative alpha stock signals in order to enrich their own stock market investment portfolios. With no need to crunch data over an extensive period of time, our freemium members pick and choose their own alpha stock signals for profitable investment opportunities in the U.S. stock market.

Smart investors can consult our proprietary alpha stock signals to ferret out rare opportunities for transient stock market undervaluation. Our analytic reports help many stock market investors better understand global macro trends in trade, finance, technology, and so forth. Most investors can combine our proprietary alpha stock signals with broader and deeper macrofinancial knowledge to win in the stock market.

Through our proprietary alpha stock signals and personal finance tools, we can help stock market investors achieve their near-term and longer-term financial goals. High-quality stock market investment decisions can help investors attain the near-term goals of buying a smartphone, a car, a house, good health care, and many more. Also, these high-quality stock market investment decisions can further help investors attain the longer-term goals of saving for travel, passive income, retirement, self-employment, and college education for children. Our AYA fintech network platform empowers stock market investors through better social integration, education, and technology.

In the current global market for better biotech advances, medical innovations, and healthcare services, the new integration of artificial intelligence (AI) reshapes the competitive landscape worldwide. - Blog - AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors.

AI-driven advances help reshape the competitive landscape for new medications, treatments, therapies...

https://ayafintech.network/blog/the-new-integration-of-artificial-intelligence-reshapes-the-competitive-landscape-for-the-global-market-for-better-medical-innovations-and-healthcare-services/

Chanel Holden

2025-03-15 04:30:55

Bullish

Quantitative fundamental analysis

Our latest podcast deep-dives into the global market for GLP-1 anti-obesity weight-loss treatments. These new medications continue to grow substantially to benefit more than 1 billion people worldwide by 2030.


$BFLY $CLDX $SDGR $NVO $LLY $JNJ $BMY $PFE $ABBV $MRK $AMGN $UNH $MRNA $AZN $DOCU 

$WMT $TGT $COST $CVS $CSCO $ORCL $IBM $ASML $SNPS $NET $CRWD $PARA $NFLX $DIS $V 

$T $VZ $TMUS $AEO $AMC $C $BAC $JPM $WFC $MS $GS $PNC $BLK $STT $IONQ $QBTS $QUBT 




This fun podcast is about 10 minutes long (with smart AI podcast generation from Google NotebookLM). https://bit.ly/4bz6vmI

The new third-generation GLP-1 medications for obesity treatment and weight loss treatment, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, now begin to become more prevalent and more pervasive worldwide. These medications show far higher weight loss efficacy than prior first-generation and second-generation medications. The latest GLP-1 medications further show long prevalent safety track records for the treatments of diabetes, heart diseases, and several kinds of cancers. However, the current U.S. prices for these new GLP-1 medications are extremely high (about $15,000 per patient per year). In the meantime, not all people with obesity can take these new GLP-1 medications because they are now prohibitively costly and U.S. insurance coverage remains partial and incomplete. Despite these current hurdles, obstacles, and impediments for broader GLP-1 drug adoption, we now expect the global market for GLP-1 obesity and weight loss medications to grow substantially to benefit more than 1 billion people with obesity worldwide by 2030.

GLP-1 medications are the first in a long history of weight loss medications to target the critical brain pathways that regulate both food intake and energy storage. As a result, GLP-1 patients feel less hungry and so crave food much less. As the third-generation medications for obesity treatment, these new GLP-1 medications often lead to 23%-25% average weight losses among GLP-1 patients (versus the single-digit average weight losses of prior medications).

While GLP-1 medications show tremendous promise in weight loss treatment, the global market for these new medications remains only a fraction of all of the people with obesity worldwide. Some patients are not medically able to take these GLP-1 medications, especially since each of these medications requires an injection by a needle. Also, these latest GLP-1 medications are shown to be effective only when patients continue to take these medications almost on a daily basis. A current lack of comprehensive insurance coverage by Medicare, Medicaid, and private insurers remains a major obstacle to wider GLP-1 drug adoption and usage in America and other countries. The current healthcare insurance programs only cover GLP-1s for the wider treatments of obesity-driven diseases such as diabetes, heart diseases, and some types of cancers, but there is now no insurance coverage solely for the treatment of obesity alone.

In addition to supply chain shortages and bottlenecks for GLP-1 mass production, the current hurdles, obstacles, and impediments impose hard high-cost limits and constraints on the size of the global market for GLP-1 medications in the near-to-medium term. Some recent estimates show that the U.S. GLP-1 patient population is likely to grow substantially from 2 million people with obesity today to at least 15 million people with obesity in 2030 (about 15% of the U.S. adults with obesity). On the basis of these recent estimates, we can now expect the global market for GLP-1 medications to increase substantially from $10 billion today to almost $100 billion by 2030.

Over the next few years, we expect U.S. employer insurance coverage for GLP-1 medications to increase substantially from approximately 50% of U.S. employers today due to greater U.S. employee healthcare needs and the significantly positive health benefits of GLP-1 medications. As several pharmaceutical titans direct their R&D efforts into some further developments of GLP-1 medications, it is reasonable for investors to expect more intense competition to result in lower prices for GLP-1 medications. Further, the new GLP-1 treatments of other obesity-driven diseases, specifically heart diseases, diabetes, and some types of cancers etc, can go a long way in empowering Medicare, Medicaid, and numerous private insurers to broaden their health insurance coverage of GLP-1 medications. In the meantime, however, U.S. Congress prohibits Medicare and Medicaid from covering GLP-1 medications today because of their budget-busting sky-high prices.

We can expect U.S. health insurance coverage to broaden substantially if the new GLP-1 medications show promise in treating serious health conditions well beyond obesity. Additional health conditions can include heart diseases, diabetes, as well as some kinds of cancers. The FDA’s recent approval of Novo Nordisk’s Wegovy, semaglutide, for the treatment of heart diseases has led to Medicare coverage of Wegovy for this new indication. Current studies for the treatments of sleep apnea, liver impairment, and other diseases can result in similarly favorable outcomes of broader Medicare coverage of GLP-1 medications. Some recent positive estimates show that the wider GLP-1 treatments of diseases can probably benefit 70 million obese U.S. patients by 2030. These positive ripple effects and chain reactions can cause greater economic benefits beyond the biotech and pharmaceutical sectors. As a result of GLP-1 medications with higher weight-loss efficacy, U.S. adults with prior obesity would have substantially greater and broader needs and demands for day-to-day food items, beverages, many other consumer staples, beauty products, and even air travel round-trips.

With the concomitant positive health improvements, the next widespread adoption of GLP-1 medications can cause better economic growth, employment, and labor productivity in America. U.S. GDP can probably rise by 0.5 to 2 percentage points in the long run if at least 30 million U.S. adults with obesity take these medications. Specifically, U.S. GDP can increase more substantially by 1.35 to 2.55 percentage points if all 70 million U.S. adults with obesity take such medications. However, the American government would face fiscal strain if both Medicare and Medicaid start to provide complete health insurance coverage to 40% of U.S. adults with obesity. This fiscal strain would likely amount to $1 trillion per year if all 40% of U.S. adults with obesity take GLP-1 medications at the current high prices ($15,000 per patient per year). This dollar amount is about the current size of Medicare and about 20% of how much Americans spend on healthcare each year. Although there are clear health benefits for U.S. adults with obesity to take GLP-1 medications, broad health insurance coverage would be enormously expensive for the U.S. government. We believe the next wave of GLP-1 technological advancements can help alleviate this fiscal concern for smarter and better healthcare solutions to weight loss treatments in due course.

With U.S. fintech patent approval, accreditation, and protection for 20 years, our AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors worldwide.

We build, design, and delve into our new and non-obvious proprietary algorithmic system for smart asset return prediction and fintech network platform automation. Unlike our fintech rivals and competitors who chose to keep their proprietary algorithms in a black box, we open the black box by providing the free and complete disclosure of our U.S. fintech patent publication. In this rare unique fashion, we help stock market investors ferret out informative alpha stock signals in order to enrich their own stock market investment portfolios. With no need to crunch data over an extensive period of time, our freemium members pick and choose their own alpha stock signals for profitable investment opportunities in the U.S. stock market.

Smart investors can consult our proprietary alpha stock signals to ferret out rare opportunities for transient stock market undervaluation. Our analytic reports help many stock market investors better understand global macro trends in trade, finance, technology, and so forth. Most investors can combine our proprietary alpha stock signals with broader and deeper macrofinancial knowledge to win in the stock market.

Through our proprietary alpha stock signals and personal finance tools, we can help stock market investors achieve their near-term and longer-term financial goals. High-quality stock market investment decisions can help investors attain the near-term goals of buying a smartphone, a car, a house, good health care, and many more. Also, these high-quality stock market investment decisions can further help investors attain the longer-term goals of saving for travel, passive income, retirement, self-employment, and college education for children. Our AYA fintech network platform empowers stock market investors through better social integration, education, and technology.

The global market for GLP-1 weight-loss medications can grow substantially to benefit more than 1 billion people worldwide by 2030. - Blog - AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors.

The global market for GLP-1 anti-obesity weight-loss medications remains in a rare unique situation ...

https://ayafintech.network/blog/the-global-market-for-GLP-1-weight-loss-medications-grows-substantially-to-benefit-1-billion-people-worldwide-by-2030/

Becky Berkman

2025-03-12 03:07:35

Bullish

Qualitative fundamental analysis

Our latest podcast deep-dives into the recent empirical results in relation to R&D innovative investment management. Specifically, we would to like to draw attention to the robust positive empirical nexus between R&D investment intensity and subsequent stock return performance.


$BFLY $CLDX $NVO $LLY $JNJ $BMY $PFE $ABBV $MRK $AMGN $UNH $MRNA $AZN $WMT $TGT 

$COST $CVS $CSCO $ORCL $IBM $ASML $SNPS $NET $CRWD $AEO $AMC $PARA $NFLX $DIS 

$T $VZ $TMUS $C $BAC $JPM $WFC $MS $GS $PNC $BLK $STT $DOCU $IONQ $QBTS $QUBT 



The original blog article is available on our AYA fintech network platform. https://ayafintech.network/blog/innovative-investment-theory-and-practice/

This fun podcast is about 10 minutes long (with smart AI podcast generation from Google NotebookLM). https://bit.ly/42Anene

Corporate investment can be in the form of real tangible investment or intangible investment. The former concerns real asset expansion through capital expenditures and mergers and acquisitions while the latter involves corporate innovation through research and development (R&D). This literature review focuses on the empirical corporate finance studies on the key implications of R&D intensity for firm performance. The other empirical corporate finance studies on capital expenditures, mergers and acquisitions, and real asset growth flow into the other separate literature reviews. These literature reviews jointly paint a more holistic picture of the empirical facts about corporate investment decisions.

Eberhart, Maxwell, and Siddique (2004) examine a sample of 8,313 cases between 1951 and 2001 where firms unexpectedly increase their R&D expenditures by a significant margin. Both the long-run buy-and-hold portfolio strategies and Fama-French-Carhart (1993, 1996, 1997) time-series regressions show that significantly positive abnormal stock returns follow these R&D increases. Also, there is robust evidence that the same sample firms experience significant improvements in long-run operating performance after the R&D increases. These empirical results reject the null efficient-markets hypothesis and thus suggest that the market is slow to recognize both the nature and extent of R&D increases as valuable investments.

Eberhart, Maxwell, and Siddique (2004) contribute to the behavioral finance literature on investor under-reaction that occurs in response to key corporate events such as SEOs, stock repurchases, and stock splits (e.g. Eberhart and Siddique (2002), Ikenberry, Lakonishok, and Vermaelen (1995, 2000), Ikenberry and Ramnath (2002), and Loughran and Ritter (1995)). This contribution echoes Daniel and Titman’s (2006) thesis that investors tend to underreact to intangible information but not to tangible information. In this sense, R&D increases provide a natural experiment to test the market’s capability to correctly incorporate the intangible content of R&D increases. To the extent that investors underreact to the intangible benefit of R&D increases, significantly positive abnormal stock returns follow these R&D increases up to the 5-year time horizon. In the larger context of a unified theory of gradual news diffusion (e.g. Jegadeesh and Titman (1993, 2001), Hong and Stein (1999), and Hong, Lim, and Stein (2000)), Eberhart, Maxwell, and Siddique’s (2004) study corroborates the behavioral story of investor underreaction to the positive effect of R&D investments on shareholder value.

Although shareholders and bondholders both benefit from an increase in firm value due to an increase in R&D investment, shareholders benefit at the expense of bondholders from a concomitant increase in firm risk because stocks are analogous to call options that bondholders implicitly sell on the underlying firm value. The benefit of an increase in R&D investment to shareholders that some earlier studies report may reveal the effect of a wealth transfer from bondholders to shareholders (Shi, 2003), not any benefit to the entire firm value. Eberhart, Maxwell, and Siddique (2008) gauge R&D investment intensity as the ratio of R&D to sales or R&D to assets and report a positive relationship between these R&D intensity metrics and bond returns. The net effect of higher R&D investment intensity is positive for bondholder value. In fact, the negative nexus between R&D intensity and default risk accords with the recent investment asset pricing conjecture (Berk, Green, and Naik, 1999; Gomes, Kogan, and Zhang, 2003; Carlson, Fisher, and Giammarino, 2004; Zhang, 2005; Cooper, 2006; Li, Livdan, and Zhang, 2009; Liu, Whited, and Zhang, 2009; Anderson and Garcia-Feijoo, 2006). As a firm invests and exercises real growth options via R&D innovation, this investment transforms the real growth options into safer assets in place with steady cash flows. As a result, the firm’s relative risk declines. Nonetheless, Eberhart, Maxwell, and Siddique’s (2008) evidence suggests a positive relation between R&D investment expansion and subsequent stock return. This evidence seems more consistent with the alternative behavioral mispricing hypothesis in contrast to the rational pricing theory.

R&D usually provides strong positive externalities because R&D investment yields benefits that accrue to parties other than the R&D investor (Bernstein and Nadiri, 1988; Jaffe, 1986). Given the positive spill-over effects of R&D investment, Chen, Chen, Liang, and Wang (2014) empirically report that there is a positive relationship between R&D incoming spillovers and firm performance improvements. This nexus indicates that the market does not immediately incorporate positive R&D externalities into stock market valuation. Chen, Chen, Liang, and Wang (2014) attribute this evidence to the behavioral story that many investors underreact to firm-specific increases in R&D investment with both positive long-term abnormal stock returns and operating performance improvements (Eberhart, Maxwell, and Siddique, 2004, 2008).

Chen, Chen, Liang, and Wang (2014) use a stochastic frontier production function to capture R&D spill-overs, which can be estimated as non-negative stochastic random covariates. Firms with high R&D spill-overs tend to recruit more key employees from other firms. Thus, firms that hire more key personnel to take advantage of technical expertise from other firms enjoy higher R&D incoming spillovers.

Chen, Chen, Liang, and Wang (2014) run the Fama-French (1993, 1996) and Carhart (1997) time-series regressions of excess stock returns that the econometrician sorts on R&D incoming spillovers. The mean monthly alpha is 0.67%-1.08% for firms with higher R&D incoming spillovers in comparison to no more than 0.58% for firms with lower R&D incoming spillovers. Thereby, R&D investments are beneficial to other firms, but the market is slow to recognize the full extent of this benefit.

Following the convention of Denis and Sarin (2001), Chan, Ikenberry, and Lee (2004), and Titman, Wei, and Xie (2004), Chen, Chen, Liang, and Wang (2014) examine abnormal stock returns around earnings announcements over the post-R&D-increase 5-year period. The evidence suggests significantly positive earnings-announcement abnormal returns for firms with high incoming spillovers, but this evidence does not hold for firms with low incoming spillovers. Thereby, the long-term stock return outperformance of R&D-intensive firms with high incoming spillovers is unlikely to be driven by benchmark measurement noise (Lyon, Barber, and Tsai, 1999).

Brown, Fazzari, and Petersen (2009) explore whether supply shifts in finance can explain a significant portion of the 1990s R&D boom and subsequent decline. With a firm-level panel dataset of 1,347 high-tech publicly traded firms from 1990 to 2004, Brown, Fazzari, and Petersen (2009) use GMM estimation of dynamic R&D models to find sharp differences in R&D finance when Brown et al split the data into young and mature firms. For mature firms, the point estimates for the financial variables are insignificant. For young firms, the measures of access to internal and external equity finance have significantly positive effects on R&D intensity. The financial effects for the young high-tech firms alone are large enough to explain most of the aggregate R&D cycle in the 1990s. In the larger context of endogenous growth theory, stock markets provide an important source of external finance and in turn contribute to economic growth by directly funding R&D innovation, particularly for young firms.

Brown, Martinsson, and Petersen (2013) analyze the explanatory power of investor protection and access to stock market finance in capturing the variation in long-term R&D intensity. Legal rules and institutions and financial developments affect the availability of external equity finance. This empirical mechanism is particularly important for risky and intangible R&D investments that are not easily financed with debt. Brown, Martinsson, and Petersen’s (2013) empirical study connects both law and finance with firm-level innovative R&D investments that help promote economic growth.

An extensive literature suggests that countries with robust legal protection of minority shareholders have larger and more accessible stock markets (La Porta, Lopez-de-Silanes, and Shleifer, 2006, 2008). Several studies report evidence of a positive relationship between stock market development and broad measures of economic growth (e.g. Levine and Zervos (1998) and Bekaert, Harvey, and Lundblad (2005)). Legal contracting institutions help enhance stock market development (Acemoglu and Johnson, 2005), and also stock market liberalization boosts aggregate productivity (Bekaert, Harvey, and Lundblad, 2011). Access to stock market finance is particularly important for R&D investments because the intangible nature of R&D with little collateral value sharply limits the firm’s ability to use debt. Since creditors share only in downside returns, the design of standard debt contracts does not work well for financing innovative R&D investments that are characterized by a high probability of failure but only some thin chance of extremely large upside returns. Thereby, legal institutions and financial developments that better facilitate access to stock market equity are more important for R&D innovative productivity growth than for tangible capital accumulation.

Brown, Martinsson, and Petersen (2013) use several exogenous instruments for legal origin, enforcement, and anti-self-dealing protection in two-stage least squares (2SLS) regressions of R&D intensity and stock market development (Demirguc-Kunt and Maksimovic, 2002; Beck and Levine, 2005; La Porta, Lopez-de-Silanes, and Shleifer, 1997, 2008). The key interaction term between stock market development and industry dependence on external finance carries a significantly positive coefficient in the small-firm and young-firm subsamples. The R&D differential measure for the interquartile range of industry dependence on external finance is significant at 2% in these subsamples.

Brown, Martinsson, and Petersen’s (2013) evidence suggests that there is a micro-level channel through which stock market development causes economic growth by supplying critical external finance to fund intangible R&D investments (which in turn help spur productivity growth) (e.g. Levine (2005: 870) and Bekaert, Harvey, and Lundblad (2011)). Further, the same evidence suggests a new nexus between legal contracting institutions and innovative R&D activities (the latter of which in turn drive economic growth) (e.g. Acemoglu and Johnson (2005)). This nexus is particularly important when R&D firms are likely to face considerable difficulty in substituting debt for equity. In addition, the interaction between financial development and access to stock market finance matters more for the R&D investment intensity among small and young firms in comparison to large and mature firms (e.g. Beck et al (2008)). In essence, the market-centric system may have a significant advantage in spurring economic growth through a sequence of creative destruction that emerges from the continual innovative R&D investments of small and young firms (e.g. Brown and Petersen (2011)).

With U.S. fintech patent approval, accreditation, and protection for 20 years, our AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors worldwide.

We build, design, and delve into our new and non-obvious proprietary algorithmic system for smart asset return prediction and fintech network platform automation. Unlike our fintech rivals and competitors who chose to keep their proprietary algorithms in a black box, we open the black box by providing the free and complete disclosure of our U.S. fintech patent publication. In this rare unique fashion, we help stock market investors ferret out informative alpha stock signals in order to enrich their own stock market investment portfolios. With no need to crunch data over an extensive period of time, our freemium members pick and choose their own alpha stock signals for profitable investment opportunities in the U.S. stock market.

Smart investors can consult our proprietary alpha stock signals to ferret out rare opportunities for transient stock market undervaluation. Our analytic reports help many stock market investors better understand global macro trends in trade, finance, technology, and so forth. Most investors can combine our proprietary alpha stock signals with broader and deeper macrofinancial knowledge to win in the stock market.

Through our proprietary alpha stock signals and personal finance tools, we can help stock market investors achieve their near-term and longer-term financial goals. High-quality stock market investment decisions can help investors attain the near-term goals of buying a smartphone, a car, a house, good health care, and many more. Also, these high-quality stock market investment decisions can further help investors attain the longer-term goals of saving for travel, passive income, retirement, self-employment, and college education for children. Our AYA fintech network platform empowers stock market investors through better social integration, education, and technology.

Innovative investment theory and practice - Blog - AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors.

Innovative investment theory and practice

https://ayafintech.network/blog/innovative-investment-theory-and-practice/

See More

Blog+More

Anat Admati and Martin Hellwig raise broad critical issues about bank capital regulation and asset market stabilization.

Charlene Vos

2023-06-07 10:27:00 Wednesday ET

Anat Admati and Martin Hellwig raise broad critical issues about bank capital regulation and asset market stabilization.

Anat Admati and Martin Hellwig raise broad critical issues about bank capital regulation and asset market stabilization. Anat Admati and Martin Hellwig (

+See More

Modern themes and insights in behavioral finance (Part 2)

Chanel Holden

2022-02-15 14:41:00 Tuesday ET

Modern themes and insights in behavioral finance (Part 2)

Modern themes and insights in behavioral finance   Lee, C.M., Shleifer, A., and Thaler, R.H. (1990). Anomalies: closed-end mutual funds. Journal

+See More

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization.

Laura Hermes

2019-09-09 20:38:00 Monday ET

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization.

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization. As Federal Reserve Ch

+See More

Chinese trade delegation offers to boost purchases of U.S. agricultural products to reach an interim trade deal with the Trump administration.

Peter Prince

2019-11-03 12:30:00 Sunday ET

Chinese trade delegation offers to boost purchases of U.S. agricultural products to reach an interim trade deal with the Trump administration.

Chinese trade delegation offers to boost purchases of U.S. agricultural products to reach an interim trade deal with the Trump administration. Chinese Vice

+See More

The OECD projects global growth to decline from 3.2% to 2.9% in the current fiscal year 2019-2020.

Rose Prince

2019-10-29 13:36:00 Tuesday ET

The OECD projects global growth to decline from 3.2% to 2.9% in the current fiscal year 2019-2020.

The OECD projects global growth to decline from 3.2% to 2.9% in the current fiscal year 2019-2020. This global economic growth projection represents the slo

+See More

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and governments.

Jonah Whanau

2019-11-15 13:34:00 Friday ET

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and governments.

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and go

+See More